- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01213316
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) (WIP)
A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria
The prospective participant must meet, at least, all of the criteria below to be eligible for study participation. The participant:
- Is a minimum age of 18 years (adults) or 50 years (aging participants);
- Is male or female;
- Has confirmed infection with HIV-1 (positive HIV test according to appropriate standard practice);
- Has commenced antiretroviral treatment with Raltegravir according to the recommendations made in the Summary of Product Characteristics at the time of enrollment on the study, or a maximum 6 months prior to enrollment on the study;
- Has any cluster of differentiation (CD4) cell (specialized white blood cell) count upon enrollment on the study.
Exclusion criteria
If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation. The participant:
- For which Raltegravir, or its ingredients, are contraindicated;
- Has intolerance to Raltegravir, or its ingredients;
- If female, is pregnant, breastfeeding, or is planning a pregnancy or egg donation during the study.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Overall Participants
HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
|
Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
Andra namn:
Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
Andra namn:
|
Aging Participants
HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany. Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort). |
Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
Andra namn:
Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With an HIV-1 Viral Load <50 Copies/mL After 48 Weeks of Raltegravir Treatment
Tidsram: Baseline and 48 weeks
|
The percentage of participants with an HIV-1 viral load <50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.
|
Baseline and 48 weeks
|
Percentage of Aging Participants With an HIV-1 Viral Load <50 Copies/mL After 48 Weeks of Raltegravir Treatment
Tidsram: Baseline and 48 weeks
|
The percentage of aging participants (>=50 years old at initiation of raltegravir treatment) with an HIV-1 viral load <50 copies/mL of HIV-1 RNA after 48 weeks of raltegravir treatment was determined.
|
Baseline and 48 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With an HIV-1 Viral Load <50 Copies/mL After 96 Weeks of Raltegravir Treatment
Tidsram: Baseline and 96 weeks
|
The percentage of participants with an HIV-1 viral load <50 copies/mL of HIV-1 RNA after 96 weeks of raltegravir treatment was determined.
|
Baseline and 96 weeks
|
HIV-1 Viral Load After 96 Weeks of Raltegravir Treatment
Tidsram: Baseline and 96 weeks
|
The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined at Baseline and after 96 weeks of raltegravir treatment.
|
Baseline and 96 weeks
|
Change From Baseline in CD4+ T-cell Counts After 96 Weeks of Raltegravir Treatment
Tidsram: Baseline and 96 weeks
|
Mean CD4+ T-cell counts were determined at baseline and after 96 weeks of raltegravir treatment.
A positive change from baseline indicates an increase in CD4+ T-cell count.
|
Baseline and 96 weeks
|
HIV-1 Viral Load in Aging Participants After 48 Weeks of Raltegravir Treatment
Tidsram: Baseline and 48 weeks
|
The HIV-1 viral load (log10 copies/mL of HIV-1 RNA) was determined in aging participants (>=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment.
|
Baseline and 48 weeks
|
Change From Baseline in CD4+ T-cell Counts in Aging Participants After 48 Weeks of Raltegravir Treatment
Tidsram: Baseline and 48 weeks
|
Mean CD4+ T-cell counts were determined in aging participants (>=50 years old at initiation of raltegravir treatment) at baseline and after 48 weeks of raltegravir treatment was determined.
A positive change from baseline indicates an increase in CD4+ T-cell count.
|
Baseline and 48 weeks
|
Change From Baseline in Mean Framingham Risk Score for the 10-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment
Tidsram: Baseline and 48 weeks
|
Mean Framingham Risk for 10-year cardiovascular risk was determined in aging participants (>=50 years old at initiation of raltegravir treatment).
Points were allotted for each of following 8 risk factors : sex, age, systolic blood pressure, treatment for hypertension, smoking, diabetes, total cholesterol, and high-density lipoprotein.
The sum of the points for each participant was assigned a percent 10-year cardiovascular risk on a lookup table, and could range from 0% to 100%.
The mean Framingham Risk for 10-year cardiovascular risk was then calculated for the analysis population.
The change from baseline was calculated as Baseline minus Week 48; a positive change indicates reduced risk.
This Outcome Measure was added with Amendment 1 and applies only to aging participants.
|
Baseline and 48 weeks
|
Change From Baseline in Mean D:A:D Risk Score for the 5-Year Cardiovascular Risk in Aging Participants After 48 Weeks of Raltegravir Treatment
Tidsram: Baseline and 48 weeks
|
Mean Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Score for 5-year cardiovascular risk was determined in aging participants (>=50 years old at initiation of raltegravir treatment) at Baseline and after 48 weeks of raltegravir treatment.
The score included the following 8 risk factors: sex, age, systolic blood pressure, family cardiovascular disease history, current smoking, previous cigarette smoker, diabetes, total cholesterol, high-density lipoprotein, currently on indinavir, currently on lopinavir, currently on abacavir, duration and current use of indinavir and duration and current use of lopinavir.
The D:A:D Risk Score is interpreted as low: <1%; moderate: 1-5%; high: 5-10%; and very high: >10%.
The change from baseline was calculated as Week 48 minus Baseline; a positive change indicates increased risk.
This Outcome Measure was added with Amendment 1 and applies only to aging participants.
|
Baseline and 48 weeks
|
Percentage of Aging Participants With Concomitant Diseases at Baseline
Tidsram: Baseline
|
The percentage of aging participants with Baseline comorbidities was reported.
This Outcome Measure was added with Amendment 1 and applies only to aging participants.
|
Baseline
|
Percentage of Aging Participants Taking Concomitant Medications at Baseline
Tidsram: Baseline
|
The percentage of aging participants taking concomitant medication in addition to their other antiretroviral therapy was reported.
This Outcome Measure was added with Amendment 1 and applies only to aging participants.
|
Baseline
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579. Epub 2008 Jan 22.
- Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991 Jan;121(1 Pt 2):293-8. doi: 10.1016/0002-8703(91)90861-b.
- Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.
- Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991 Jan;83(1):356-62. doi: 10.1161/01.cir.83.1.356. No abstract available.
- Naumann U, Moll A, Schleehauf D, Lutz T, Schmidt W, Jaeger H, Funke B, Witte V. Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort. Int J STD AIDS. 2017 Aug;28(9):893-901. doi: 10.1177/0956462416679550. Epub 2016 Nov 14. Erratum In: Int J STD AIDS. 2017 Jun;28(7):738.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- RNA-virusinfektioner
- Virussjukdomar
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunsystemets sjukdomar
- Långsamma virussjukdomar
- HIV-infektioner
- Infektioner
- Förvärvat immunbristsyndrom
- Immunologiska bristsyndrom
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- HIV-integrashämmare
- Integrashämmare
- Raltegravir kalium
Andra studie-ID-nummer
- 0518-145
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-1-infektion
-
Institut PasteurRekrytering
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University... och andra samarbetspartnersAvslutadHIV-1Burkina Faso, Zambia
-
Hospital Universitari Vall d'Hebron Research InstituteGilead SciencesAvslutad
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixaAvslutad
-
Gilead SciencesAvslutad
-
University of AarhusAarhus University Hospital Skejby; Bandim Health Project; Abbott; Ministry...Avslutad
-
Tibotec Pharmaceuticals, IrelandAvslutadHIV-1Förenta staterna, Frankrike, Spanien, Portugal, Kanada, Storbritannien, Sydafrika, Argentina, Brasilien, Puerto Rico, Thailand, Nederländerna, Rumänien
-
Tibotec Pharmaceuticals, IrelandAvslutadHIV-1Förenta staterna, Kanada, Frankrike, Belgien, Tyskland, Spanien, Argentina, Chile, Panama, Brasilien, Puerto Rico, Thailand, Mexiko, Australien
-
Mymetics CorporationInstitut Cochin; San Raffaele University Hospital, Italy; Kinesis Pharma... och andra samarbetspartnersAvslutad
-
Janssen Pharmaceutica N.V., BelgiumAvslutad
Kliniska prövningar på Raltegravir
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AvslutadHIV-infektionerFörenta staterna, Puerto Rico, Sydafrika, Argentina, Brasilien, Botswana
-
ViiV HealthcareAvslutadInfektion, humant immunbristvirusFörenta staterna
-
Merck Sharp & Dohme LLCAvslutad
-
ViiV HealthcareGlaxoSmithKline; ShionogiAvslutadHIV-infektioner | Infektion, humant immunbristvirusFörenta staterna, Frankrike, Nederländerna, Spanien, Taiwan, Australien, Belgien, Ryska Federationen, Kanada, Storbritannien, Mexiko, Italien, Sydafrika, Rumänien, Argentina, Ungern, Polen, Chile, Grekland, Brasilien
-
ViiV HealthcareGlaxoSmithKline; ShionogiAvslutadInfektion, humant immunbristvirus ITyskland, Spanien, Frankrike, Australien, Förenta staterna, Kanada, Storbritannien, Italien, Ryska Federationen
-
Bristol-Myers SquibbMerck Sharp & Dohme LLCAvslutad
-
Universidad Peruana Cayetano HerediaMerck Sharp & Dohme LLCAvslutadHTLV-I-infektioner | Tropisk spastisk paraparesPeru
-
ANRS, Emerging Infectious DiseasesAvslutadHIV-1-infektion | GRAVIDITETFrankrike
-
National Institute of Neurological Disorders and...Avslutad